Induced Pluripotent Stem Cell Market Segmentation By Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Neurons, Others); By Application ( Drug Development, Regenerative Medicine, Toxicity Testing); By End User (Academic and Research Institutes, Biotechnology Companies) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2026

Overview of the iPS Cell Market with Reference to the Global Healthcare Sector Outlook

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare

• Current expenditure on health, % of gross domestic product
• Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs)
• Annual growth rate of current expenditure on health, per capita, in real terms
• Out-of-pocket expenditure, % of current expenditure on health
• Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs)
• Physicians, Density per 1000 population (head counts)
• Nurses, Density per 1000 population (head counts)
• Total hospital beds, per 1000 population
• Curative (acute) care beds, per 1000 population
• Medical technology, Magnetic Resonance Imaging units, total, per million population
• Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

PMR utilizes a triangulation methodology that is primarily based on overall expenditure on life science research and R&D funding and capital equipment installed base to obtain precise market estimations and insights on life science and biotechnology associated products, technologies, applications and services. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country-specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product and service offerings, equipment installed base in end use facilities, adoption rate and future impact of new technologies. Additionally, per capita consumption of kits, reagents and consumables among end users is tracked at a granular level to obtain the most accurate information. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side respondents such as laboratory managers, procurement managers, research supervisors at academic and research institutes, as well as key opinion leaders in addition to supply-side respondents such as equipment and reagent manufacturers, custom solution and service providers who provide valuable insights on trends, research application of products and technologies, purchasing patterns, services offered and associated pricing.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project year-on-year growth rates. These Y-o-Y growth projections are checked and aligned as per associated industry/product lifecycles and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse annual reports of various companies, investor presentations, SEC filings, 10k reports and earning call transcripts operating in the market to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at tier-level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as overall life science research expenditure, R&D funding, industry based demand driving factors impacting the market and its forecast trends apart from other macroeconomic factors.

Standard Report Structure

• Executive Summary
• Market Definition
• Macro-economic analysis
• Parent Market Analysis
• Market Overview
• Forecast Factors
• Segmental Analysis and Forecast
• Regional Analysis
• Competition Analysis

Market Taxonomy

The global iPS cell market has been segmented into:

Cell Type

• Hepatocytes
• Fibroblasts
• Keratinocytes
• Neurons
• Others

Application

• Drug Development
• Regenerative Medicine
• Toxicity Testing

End User

• Academic and Research Institutes
• Biotechnology Companies

Region

• North America
• Latin America
• Europe
• Asia Pacific excluding China (APEC)
• China
• Middle East and Africa (MEA)

Despite the presence of several large-scale players as well as multiple regional companies in the global iPS cell market, there are very limited companies that have a complete focus on being a provider of life science reagents and products. Different manufacturers have different product offerings and specializations, with most large companies combining research products and reagents with equipment and in-vitro diagnostics tools. Having a sole focus on this market ensures better quality of products, customer loyalty and an established distribution network that can increase the availability of the product across the globe. The spending by companies on the research and development pertaining to life sciences is expected to provide lucrative prospects for growth. Companies investing in providing tools and products to cater to the research requirements of several healthcare providers and research institutes can expect to see stable returns.

Growing investment in basic level research, especially by research organizations and academic institutes in the last few years has led to an increased understanding of the fundamental pathways through which iPSCs implicated in disease development are either up or down-regulated. This leads to more questions about how biology works, the cause of the diseases and potential diagnoses and treatments. Induced pluripotent stem cells display a particular gene expression signature that is similar to that of embryonic stem cells (ESCs) and exhibit both pluripotency and the capacity of self-renewal. In the recent past, the complexity of products requested by researchers has grown and this suggests improvement in understanding of the basic pathways and discovery of some new pathways. It is important for manufacturers of research products to keep up with the latest developments to cater to the ever-changing requirements of the life sciences industry.

North America is expected to lead the global market given the rising number of research and clinical trials in the region

In the last few years, drug toxicity screening was a difficult process owing to the lack of human samples and thus, researchers relied on immortalized cell-based assays or in-vivo animal models for clinical trials and research. Advancements in iPSC technology in North America in several research institutes has enabled a steady supply of functional cells for pre-clinical screening of drugs. Moreover, iPSCs offers a unique platform that allows researchers to model diseases on a patient-by-patient basis. This micromedicine procedure makes it possible to understand the progression of the disease at an individual patient level and also screen for optimal pharmacological drugs individually. High-throughput analyses for drug toxicity that use human iPSC-CMs can also be conducted using macromedicine, under which iPSC-based medicine could be applied to cohorts of patients. In these clinical trials, iPSCs generated from patients could be differentiated with functional cells and are used to analyze the effectiveness of the drugs. The ongoing research in the region is expected to pave the way for future investments in the market.

Europe will also gear up in the game with the growth of the contract research industry

Europe has recently become the hub for small and large-scale biopharmaceutical companies and has become dependent on the contract research organization sector and other clinical services for research and development operations. Outsourcing of iPSCs trials has eventually bolstered the process of drug approval and will help Europe retain its place in the global market.

Company Profile

• Thermo Fisher Scientific Inc.
• FUJIFILM Holdings Corporation (Cellular Dynamics)
• Horizon Discovery Group plc.
• Takara Bio Inc.
• Cell Applications, Inc.
• Lonza Group Ltd.
• Others.